These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16966296)

  • 21. Prolymphocytic leukemia or prolymphocytic transformation of mantle cell lymphoma.
    Veillon DM; Nordberg ML; Glass J; Sattar T; Cotelingam JD
    Am J Clin Pathol; 2001 Nov; 116(5):781-2. PubMed ID: 11710698
    [No Abstract]   [Full Text] [Related]  

  • 22. Bone marrow histological patterns in B-cell and T-cell prolymphocytic leukemia.
    Nieto LH; Lampert IA; Catovsky D
    Hematol Pathol; 1989; 3(2):79-84. PubMed ID: 2777734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T-cell prolymphocytic leukemia.
    Dearden CE
    Med Oncol; 2006; 23(1):17-22. PubMed ID: 16645226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cutaneous infiltration in T-cell prolymphocytic leukaemia.
    Mallett RB; Matutes E; Catovsky D; Maclennan K; Mortimer PS; Holden CA
    Br J Dermatol; 1995 Feb; 132(2):263-6. PubMed ID: 7888364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T-cell prolymphocytic leukemia involving extramedullary sites.
    Valbuena JR; Herling M; Admirand JH; Padula A; Jones D; Medeiros LJ
    Am J Clin Pathol; 2005 Mar; 123(3):456-64. PubMed ID: 15716243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolymphocytic leukemia with suppressor T-cell phenotype: report of two cases.
    Jehn U; Grunewald R; Göldel N; Meissner H; Greither L; Thiel E; Müller D
    Anticancer Res; 1989; 9(1):115-8. PubMed ID: 2523211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of fludarabine in end-stage prolymphocytic leukemia.
    Doorduijn JK; Michiels JJ
    Leukemia; 1994 Aug; 8(8):1439. PubMed ID: 8057685
    [No Abstract]   [Full Text] [Related]  

  • 28. Small cell variant type of T-prolymphocytic leukemia with a four-year indolent course preceding acute exacerbation.
    Shimizu D; Nomura K; Matsumoto Y; Nishida K; Taki T; Horiike S; Inaba T; Fujita N; Taniwaki M
    Leuk Lymphoma; 2006 Jun; 47(6):1170-2. PubMed ID: 16840216
    [No Abstract]   [Full Text] [Related]  

  • 29. Development of aggressive T-cell leukemia at 1 month after the diagnosis of hypereosinophilic syndrome.
    Yamamoto K; Doki N; Oshikawa G; Hanata N; Takizawa Y; Kubota N; Inoue M; Hagihara M; Kobayashi T; Kakihana K; Sakamaki H; Ohashi K
    Leuk Lymphoma; 2014 Oct; 55(10):2402-4. PubMed ID: 24438196
    [No Abstract]   [Full Text] [Related]  

  • 30. Phenotypic transformation of CD52(pos) to CD52(neg) leukemic T cells as a mechanism for resistance to CAMPATH-1H.
    Birhiray RE; Shaw G; Guldan S; Rudolf D; Delmastro D; Santabarbara P; Brettman L
    Leukemia; 2002 May; 16(5):861-4. PubMed ID: 11986948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new case of Sézary cell leukemia: a morphological variant of prolymphocytic leukemia.
    Pérez-Vila Mf; Espinet B; Solé F; Pedro C; Woessner S; Florensa L
    Haematologica; 2000 Jul; 85(7):775-6. PubMed ID: 10897140
    [No Abstract]   [Full Text] [Related]  

  • 32. Circulating blastoid cells: acute leukemia, prolymphocytic leukemia, or something else?
    Zhao Y; Rehder C; Wang E
    Ann Hematol; 2021 Dec; 100(12):3047-3048. PubMed ID: 32929583
    [No Abstract]   [Full Text] [Related]  

  • 33. Complete response to alemtuzumab in a patient with B prolymphocytic leukemia.
    Chaar BT; Petruska PJ
    Am J Hematol; 2007 May; 82(5):417. PubMed ID: 17160995
    [No Abstract]   [Full Text] [Related]  

  • 34. B-CLL in PLL transformation associated with hypercalcemia.
    Lerner D; Esteves C; De Oliveira MS
    Leuk Lymphoma; 1994 Jan; 12(3-4):321-5. PubMed ID: 8167564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mature T-cell leukemias.
    Ravandi F; Kantarjian H; Jones D; Dearden C; Keating M; O'Brien S
    Cancer; 2005 Nov; 104(9):1808-18. PubMed ID: 16136598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improvement of quality of life after splenectomy in an HTLV-I carrier with T-cell prolymphocytic leukemia.
    Sakai R; Maruta A; Tomita N; Taguchi J; Fujisawa S; Ogawa K; Motomura S; Kodama F; Mohri H; Ishigatsubo Y
    Leuk Lymphoma; 1999 Nov; 35(5-6):607-11. PubMed ID: 10609799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sustained response of refractory prolymphocytic leukemia to fludarabine.
    Sporn JR
    Acta Haematol; 1991; 85(4):209-11. PubMed ID: 1853684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cutaneous localization of T-cell prolymphocytic leukemia].
    Thomas A; Dompmartin A; Troussard X; Moreau A; Manard C; Leroy D
    Ann Dermatol Venereol; 1995; 122(8):526-9. PubMed ID: 8572493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The WHO classification of mature T-cell leukemias.
    Catovsky D; Matutes E; Dearden C; Osuji N; Brito-Babapulle V
    Blood; 2004 Nov; 104(9):2989-90; author reply 2990. PubMed ID: 15498862
    [No Abstract]   [Full Text] [Related]  

  • 40. [Chronic lymphocytic and prolymphocytic leukemia].
    Gerrits CJ; Michiels JJ
    Ned Tijdschr Geneeskd; 1995 Apr; 139(16):826-30. PubMed ID: 7731474
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.